Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.750 +0.040 (+2.34%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 14, 2026 Add to My Watchlist

Price and Volume

Volume	1,257,529
Open	1.700
Bid (Size)	1.720 (1,000)
Ask (Size)	1.750 (500)
Prev. Close	1.710
Today's Range	1.700 - 1.790
52wk Range	0.4800 - 1.840
Shares Outstanding	144,474,452
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

March 24, 2026

Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

March 23, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	+53.5%	+53.5%
1 Month	+8.7%	+8.7%
3 Month	+45.8%	+45.8%
6 Month	+19.9%	+19.9%
1 Year	+230.2%	+230.2%

More News

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

March 11, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon (LXRX) Q4 2025 Earnings Call Transcript ↗

March 05, 2026

Via The Motley Fool

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Beats Q4 Estimates and Strengthens Cash Runway ↗

March 05, 2026

Via Chartmill

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

March 05, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

March 03, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

February 26, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends ↗

January 24, 2026

Via Chartmill

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

January 30, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Announces Proposed Public Offering of Common Stock

January 29, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

January 23, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

January 21, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

January 09, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Get insights into the top gainers and losers of Wednesday's pre-market session. ↗

December 31, 2025

Via Chartmill

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

December 10, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

December 05, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

November 25, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 17, 2025

Via Benzinga

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

November 11, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

November 08, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q3 2025 Earnings Surpass Expectations, Fueling Pre-Market Rally ↗

November 06, 2025

Via Chartmill

Frequently Asked Questions

Is Lexicon Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Lexicon Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Lexicon Pharmaceuticals, Inc. - Common Stock trade on?

Lexicon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock is LXRX on the Nasdaq Stock Market

What is the current price of Lexicon Pharmaceuticals, Inc. - Common Stock?

The current price of Lexicon Pharmaceuticals, Inc. - Common Stock is 1.750

When was Lexicon Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Lexicon Pharmaceuticals, Inc. - Common Stock was at 04/14/26 04:00 PM ET

What is the market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock is 252.83M

How many shares of Lexicon Pharmaceuticals, Inc. - Common Stock are outstanding?

Lexicon Pharmaceuticals, Inc. - Common Stock has 253M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.